
Alligator’s CEO: “I’m confident that we will strike a deal”
Alligator Bioscience is currently conducting a rights issue aimed at advancing mitazalimab towards phase III and securing a partnership. CEO Søren Bregenholt joins BioStock’s studio to discuss the recently announced cost-saving program, mitazalimab’s clinical data, and the company’s efforts to achieve a partnership for the candidate.
– A number of companies are doing due diligence, says Søren Bregenholt.
Watch the interview below:

This material has been prepared for marketing purposes and is not, and should not be considered, a prospectus according to applicable laws and regulations. The complete terms of the rights issue and more information about the company have been presented in a prospectus that has been disclosed and published on the aforementioned company’s website.
Artikelns innehåll är sponsrat av det aktuella bolaget som förekommer i texten. BioStock tillhandahåller inte investeringsrådgivning, förmedlar inga investeringsorder och tar inget ansvar för agerande och/eller eventuell förlust eller skada av något slag som grundar sig på användandet av innehåll som publicerats på BioStock.se. Varje investeringsbeslut fattas istället självständigt av den enskilde investeraren.